Influence Mapping: The New Blueprint for Marketing Impact
For years, marketing strategy followed the linear funnel. A consumer would move...
Read More
Navigating HR's Regulatory Labyrinth
Today’s HR professionals are at the forefront of an unprecedented wave of...
Read More
Ipsen's Strategic Transformation: A Comprehensive Case Study
David Loew took over as CEO of Ipsen during a turbulent period marked by a 70% drop in share price due to the FDA’s hold on palovarotene, a drug for a rare bone disease. Concurrently, their flagship product, Somatuline, faced new generic competition, and the company’s R&D pipeline was heavily skewed towards late-stage assets, posing significant challenges.
Read More